Premier Biomedical Inc

As of December 31, 2019, Premier Biomedical Inc carries a market capitalization of 104,844.59, placing it among publicly traded companies globally. Its enterprise value stands at 196,529.59, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2019, Premier Biomedical Inc has 262.11M shares outstanding.

These figures are as of December 31, 2019. The price-to-sales ratio is 2.15, and the price-to-book ratio stands at -0.06.

These figures are as of December 31, 2019. The EV/Sales ratio of 13.76 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 196,529.59 versus a market cap of 104,844.59, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2019, Premier Biomedical Inc maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -8.77, indicating conservative leverage, while an interest coverage ratio of -0.83 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2019. Return on assets (ROA) is negative at -281.63, reflecting losses generated across the asset base. Inventory turnover of 0.66 indicates how many times Premier Biomedical Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Premier Biomedical Inc's stock has gained approximately 20.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Over the twelve months ended December 31, 2019, Premier Biomedical Inc generated 14,281.00 in revenue and converted that into -374,470.00 in net income, yielding earnings per share of 0.00. EBITDA reached -323,905.00, while operating income came in at -326,735.00.

As of December 31, 2019, Premier Biomedical Inc holds 71,197.00 in cash and equivalents against 160,748.00 in total debt, resulting in a net debt position of 89,551.00. Total book value stands at -1.83M, with working capital of -1.84M providing operational flexibility.

Premier Biomedical Inc produced -344,180.00 in operating cash flow over the twelve months ended December 31, 2019. After subtracting -4,850.00 in capital expenditures, free cash flow totaled -349,030.00 - equivalent to 0.00 per share.

Over the twelve months ended December 31, 2019, Premier Biomedical Inc posted a gross margin of 9.95, reflecting its pricing power and cost economics. The operating margin of -2,287.90 and net profit margin of -2,622.16 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2019. Free cash flow yield is negative at -1,139.10: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -317.99, meaning Premier Biomedical Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Premier Biomedical Inc's most recent stock split took place on June 27, 2018 with a 250:1 split ratio.

As of December 31, 2019, Premier Biomedical Inc has an Altman Z-Score of -269.58, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.